Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

4:15 PM ET 8-K
Financial Results Lyell Immunopharma, Inc. LYEL

Lyell Immunopharma Financial Results

Lyell Immunopharma reported Q3 2026 financial results and provided clinical updates for its CAR T-cell therapy ronde-cel, which showed a 91% overall response rate in the PiNACLE trial. The company also announced an $80 million private placement financing, extending its cash runway into 2028.

“The updated ronde-cel data accepted for presentation at ASH further strengthen our conviction in ronde-cel’s potential to meaningfully improve outcomes for patients with large B-cell lymphoma. The high rates of very durable complete responses achieved by ronde-cel in both the second- and third- or later-line settings, including in patients with high-risk primary refractory disease, clearly showcase the next-generation potential of ronde-cel.”

Lynn Seely, M.D., President and Chief Executive Officer of Lyell
4:15 PM ET 10-Q
Financial Results Trimble Inc. TRMB

Trimble Q3 2026 Results: Net Income $59.1M, Down 47.0% YoY

Trimble Inc. reported a net loss of $313.7 million for the first three quarters of 2026, primarily driven by a $562.0 million goodwill impairment charge. Despite the net loss, total revenue grew to $2,878.7 million compared to $2,617.5 million in the prior year period, supported by strong growth in subscription and services revenue.

Key figure
Net income $59.1M · -47.0% YoY
4:14 PM ET 10-Q
Financial Results Sera Prognostics, Inc. SERA

Sera Prognostics Q3 2026 Results: Net Loss of $8.05M, Loss Widens

Sera Prognostics, Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued commercialization efforts for its PreTRM test. The company maintained a strong cash position while focusing on expanding clinical evidence and market adoption to drive long-term growth.

Key figure
Net loss $8.05M
4:14 PM ET 8-K
Financial Results Cava Group, Inc. CAVA

Cava Group Financial Results

CAVA Group reported third quarter 2026 revenue of $353.7 million, a 22.1% increase year-over-year, driven by 102 net new restaurant openings and 3.1% same-restaurant sales growth. The company reached a milestone of 500 total restaurants during the quarter, though net income slightly decreased to $13.2 million from $14.7 million in the prior year due to higher depreciation and labor investments.

Term
Q3 2026

“In the third quarter, despite broader industry pressures, we continued to gain market share, expand our footprint, and see strong performance from our new restaurants. Same Restaurant Sales grew 3.1%, CAVA Revenue increased 22.1%, and we opened our 500th restaurant ahead of schedule. As we look ahead, we will continue investing in our teams and our guests, strengthening the lasting relationships that support durable growth.”

Brett Schulman, Co-Founder and CEO
4:14 PM ET 8-K
Financial Results ThredUp Inc. TDUP

ThredUp Financial Results

ThredUp reported Q3 2026 revenue of $88.2 million, a 7% year-over-year increase, alongside record active buyers of 1.82 million. Despite the growth in scale, the company reported a net loss of $5.5 million and updated its full-year 2026 revenue guidance to a range of $337.7 million to $339.7 million.

Term
Q3 2026

“We're proud to report a record quarter for active buyers, orders and items sold, delivering clear value for our buyers in Q3. Even as we navigate a highly competitive environment, we remain focused on innovating across the product experience to compound our competitive advantages as a managed marketplace.”

James Reinhart, ThredUp CEO and co-founder
4:14 PM ET 8-K
Financial Results Tenaya Therapeutics, Inc. TNYA

Tenaya Therapeutics Financial Results

Tenaya Therapeutics reported third quarter 2026 financial results, ending the period with $66.8 million in cash which provides a runway into Q4 2027. The company highlighted the recent FDA RMAT designation for its TN-401 gene therapy and expects to provide clinical data updates and pivotal trial planning feedback for both TN-201 and TN-401 by year-end.

“As we celebrate the tenth anniversary of Tenaya, we are entering one of the most important periods in the Company’s history. The forthcoming data updates from TN-201 and TN-401, together with regulatory feedback on potential pivotal development pathways, are expected to inform potential opportunities to advance these programs toward late-stage development.”

Faraz Ali, Chief Executive Officer of Tenaya
4:14 PM ET 10-Q
Financial Results AdvanSix Inc. ASIX

AdvanSix Q3 2026 Results: Net Loss of $7.55M, Loss Widens

AdvanSix Inc. reported a net loss of $7.6 million for the third quarter of 2026, compared to a net loss of $2.6 million in the prior year period, despite a sales increase to $430.8 million. For the nine months ended September 30, 2026, the company recorded a net loss of $19.9 million, a significant decline from the $52.1 million net income reported in the same period of 2025.

Key figure
Net loss $7.55M
4:14 PM ET 8-K
Financial Results Acadia Pharmaceuticals Inc ACAD

Acadia Pharmaceuticals Financial Results

Acadia Pharmaceuticals reported Q3 2026 total revenues of $342 million, a 22% increase year-over-year, driven by strong sales of DAYBUE and NUPLAZID. The company raised its 2026 net sales guidance for DAYBUE to $505–$520 million and highlighted upcoming Phase 2 readouts for its pipeline candidates in 2027.

Term
Q3 2026

“Acadia delivered a strong third quarter, with total revenues of $342 million and continued commercial momentum across DAYBUE and NUPLAZID. In the U.S., DAYBUE delivered another strong quarter, supported by meaningful uptake of DAYBUE STIX. In Europe, we are excited to build momentum following our recent launch of DAYBU in Germany. NUPLAZID also performed well, driven by underlying demand and the continued expansion of our commercial reach.”

Catherine Owen Adams, Chief Executive Officer of Acadia
4:14 PM ET 10-Q
Financial Results Abbott Laboratories ABT

Abbott Laboratories Q3 2026 Results: Net Income $920M, Down 44.0% YoY

Abbott Laboratories completed the $20.6 billion acquisition of Exact Sciences in March 2026, significantly expanding its cancer diagnostics portfolio. The company reported net earnings allocated to common shares of $2.9 billion for the first nine months of 2026, while managing a contract liability balance of $669 million and a goodwill increase to $32.6 billion.

Key figure
Net income $920M · -44.0% YoY
4:14 PM ET 10-Q
Financial Results Madison Square Garden Entertainment Corp. MSGE

Madison Square Garden Entertainment Q1 2026 Results: Turns Profitable, Net Income $8.91M

For the three months ended September 30, 2026, Madison Square Garden Entertainment Corp. reported total revenues of $217.1 million, a significant increase from $158.3 million in the prior year period. The company achieved a net income of $8.9 million, or $0.19 per diluted share, compared to a net loss of $21.7 million in the same quarter of 2025.

Key figure
Net income $8.91M
4:14 PM ET 8-K
Financial Results 8X8 Inc EGHT

8X8 Financial Results

8x8, Inc. reported record second quarter fiscal 2027 results with total revenue of $192 million, up 4% year-over-year, and service revenue of $188 million. The company achieved GAAP net income of $3.4 million and raised its full-year fiscal 2027 outlook for revenue, profitability, and operating cash flow based on strong performance and accelerating AI solution adoption.

Term
Q2 2027

“We delivered our sixth consecutive quarter of year-over-year revenue growth, and our second quarter outperformance led us to raise our full-year outlook for revenue, profitability and operating cash flow. We have a growing business and significant opportunities to build on it. AI is increasing the value of the conversations we already power, and our global voice network, unified platform and native AI development environment position us to capture that opportunity. Our focus is on turning these advantages into broader customer adoption, profitable growth and long-term shareholder value.”

Samuel Wilson, Chief Executive Officer at 8x8, Inc.
4:14 PM ET 8-K
Financial Results Socket Mobile, Inc. SCKT

Socket Mobile Financial Results

Socket Mobile reported Q3 2026 revenue of $3.4 million, a 9% year-over-year increase, and narrowed its operating loss to $643,000. The company highlighted sequential revenue growth and a 10% year-over-year reduction in operating expenses as part of ongoing cost management initiatives.

Term
Q3 2026

“Our third-quarter results reflect progress in stabilizing revenue while executing our cost management initiatives. Revenue increased 12% sequentially from the second quarter and 9% compared with the prior-year quarter, reflecting improved performance amid continued market uncertainty. At the same time, we continued to align our cost structure with business conditions, reducing operating expenses by 12% from the prior quarter and 10% year over year. These results reflect our ongoing focus on operational efficiency and financial discipline while maintaining our ability to support customers and pursue future growth opportunities.”

Dave Holmes, President and Chief Executive Officer
4:14 PM ET 8-K
Financial Results Pennant Group, Inc. PNTG

Pennant Group Financial Results

The Pennant Group reported third quarter 2026 financial results, featuring a 32% year-over-year revenue increase to $302.3 million. The company achieved GAAP diluted EPS of $0.26 and adjusted diluted EPS of $0.35, driven by strong growth in its Home Health and Hospice Services segment.

Term
Q3 2026
4:13 PM ET 10-Q
Financial Results Compass Diversified Holdings CODI

Compass Diversified Holdings Q3 2026 Results: Turns Profitable, Net Income $21.5M

Compass Diversified Holdings reported its Q3 2026 results following a period of significant disruption caused by an internal investigation into its Lugano subsidiary, which resulted in Lugano's deconsolidation and subsequent liquidation effective September 30, 2026. The company is currently focused on internal control remediation, deleveraging, and managing the impact of suspended common share distributions and limited capital market access.

Key figure
Net income $21.5M
4:13 PM ET 10-Q
Financial Results Compass Group Diversified Holdings LLC CODI

Compass Group Diversified Holdings Q3 2026 Results: Turns Profitable, Net Income $21.5M

Compass Diversified Holdings reported its Q3 2026 results following a period of significant disruption caused by an internal investigation into its Lugano subsidiary, which resulted in deconsolidation and bankruptcy. The company is currently focused on internal control remediation, deleveraging, and managing professional fees related to the Lugano Investigation while maintaining its 2022 Credit Facility.

Key figure
Net income $21.5M
4:13 PM ET 8-K
Financial Results Motorola Solutions, Inc. MSI

Motorola Solutions Financial Results

Motorola Solutions reported third-quarter 2026 sales of $3.4 billion, up 12% year-over-year, driven by strong demand in safety and security solutions. The company achieved a record ending backlog of $16.6 billion and raised its full-year revenue and earnings outlook for the second time this year.

Term
Q3 2026

“Q3 was another outstanding quarter, with double-digit revenue growth across both segments and all three technologies. We continue to see exceptionally strong demand across our safety and security solutions, driving record Q3 orders and an all-time record ending backlog. As a result, we’re raising our revenue and earnings outlook again and increasing our cash flow expectations for the full year.”

Greg Brown, chairman and CEO, Motorola Solutions
4:13 PM ET 10-Q
Financial Results TKO Group Holdings, Inc. TKO ▶ Call

TKO Group Holdings Q3 2026 Results: Net Income $98.7M, Up 140.7% YoY

TKO Group Holdings, Inc. filed its 10-Q for the period ending September 30, 2026, following the 2025 Endeavor Asset Acquisition of IMG, On Location, and PBR. The filing highlights the company's dual-class share structure and its dependence on media rights, content distribution agreements, and key executive management.

Key figure
Net income $98.7M · +140.7% YoY
4:13 PM ET 8-K
Financial Results Zevia PBC ZVIA

Zevia PBC Financial Results

Zevia PBC reported Q3 2026 financial results with net sales growing 18.4% year-over-year to $48.3 million, exceeding its previous guidance. The company improved its net loss to $2.2 million and raised its full-year 2026 outlook for both net sales and Adjusted EBITDA.

Term
Q3 2026

“Our better-than-expected third quarter results, combined with strong execution against our key focus areas and encouraging proof points across the business, reinforce our confidence in Zevia’s trajectory. With a stronger foundation, significant liquidity and additional capital, we are entering an exciting new chapter for our business. We believe we now have the resources, momentum and strategic plan to accelerate our growth and create shareholder value over the long term.”

Alexandre Ruberti, President and CEO of Zevia
4:13 PM ET 8-K
Financial Results Sight Sciences, Inc. SGHT

Sight Sciences Financial Results

Sight Sciences reported record third-quarter 2026 revenue of $24.9 million, a 25% increase year-over-year, driven by significant growth in its Interventional Dry Eye segment. The company improved its net loss to $6.8 million and raised its full-year 2026 revenue guidance to a range of $99.1 million to $101.1 million.

“We delivered another strong quarter with 25% total revenue growth, record IDE revenue, continued IG revenue growth, and a significant reduction in cash burn. These results demonstrate increasing adoption of our technologies, disciplined execution across our organization, and our growing impact on patients with glaucoma and dry eye disease.”

Paul Badawi, Co-Founder and CEO of Sight Sciences
4:13 PM ET 8-K
Financial Results Progyny, Inc. PGNY

Progyny Financial Results

Progyny reported record third-quarter 2026 results with revenue increasing 9% year-over-year to $341.3 million and net income nearly doubling to $26.3 million. The company achieved its strongest selling season ever, adding 1.3 million new covered lives for 2027 while maintaining near 100% client retention.

“We're exceptionally pleased with the results of our most recent selling season, where our momentum extended even into its latest stages, yielding 1.3 million new covered lives, our most ever in a single season, and over 85 new clients.”

Pete Anevski, Chief Executive Officer of Progyny

“We achieved strong top- and bottom-line growth this quarter, reflecting that member engagement was consistent with our expectations, and we are pleased to be in a position to raise the midpoint of our full year guidance.”

Mark Livingston, Chief Financial Officer of Progyny
4:13 PM ET 8-K
Financial Results Caris Life Sciences, Inc. CAI

Caris Life Sciences Financial Results

Caris Life Sciences reported Q3 2026 revenue of $275.4 million, a 27% increase year-over-year, driven by strong molecular profiling clinical case volume. The company raised its full-year 2026 revenue guidance to a range of $1.04 billion to $1.05 billion and reported positive net income of $15.3 million for the quarter.

Term
Q3 2026

“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year. Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey.”

David Dean Halbert, Founder, Chairman and CEO
4:12 PM ET 8-K
Financial Results American Homes 4 Rent, L.P. AMH

American Homes 4 Rent Financial Results

American Homes 4 Rent (AMH) reported Q3 2026 financial results with total revenues increasing 4.1% year-over-year to $498.1 million. The company raised its full-year 2026 Core FFO guidance midpoint to $1.97 per share and repurchased $75 million of its Class A common shares during the quarter.

Term
Q3 2026

“AMH had another strong quarter with balanced execution across the platform and resilient demand driving an increase to the midpoint of our Core FFO per share guidance by $0.02 to $1.97 – now representing 5.3% year-over-year growth. Our high-quality homes in great locations, superior resident experience supported by our technology and data platform, and outstanding team continue to differentiate AMH and drive sector-leading growth as we close out 2026 and turn our attention to 2027.”

Bryan Smith, AMH’s Chief Executive Officer
4:12 PM ET 8-K
Financial Results Stabilis Solutions, Inc. SLNG

Stabilis Solutions Financial Results

Stabilis Solutions reported Q3 2026 revenue of $14.8 million and net income of $0.2 million, marking a sequential recovery from a net loss in the previous quarter. The results were driven by growth in data center-related revenue, which rose to 17% of total revenue, and a 49% year-over-year increase in aerospace sector revenue.

“Our third quarter results were in line with our expectations and reflect the sequential improvement we anticipated, with revenues of $14.8 million supported by execution of a short-term power generation contract secured earlier this year.”

Casey Crenshaw, Executive Chairman and Interim President & Chief Executive Officer

“Demand for small-scale LNG solutions to support behind-the-meter power generation at data centers remains robust, and we continue to pursue additional opportunities in this market that would extend our growth beyond the contracts already in hand.”

Casey Crenshaw, Executive Chairman and Interim President & Chief Executive Officer
4:12 PM ET 10-Q
Financial Results Rapid7, Inc. RPD

Rapid7 Q3 2026 Results: Net Income $3.51M, Down 64.2% YoY

Rapid7 reported a slight decrease in total revenue to $633.0 million for the first nine months of 2026 compared to $642.4 million in 2025. Despite the revenue dip, the company achieved a net income of $10.7 million, supported by a reduction in total operating expenses and a restructuring initiative that incurred $11.7 million in costs.

Key figure
Net income $3.51M · -64.2% YoY
4:12 PM ET 8-K
Financial Results Snap Inc SNAP

Snap Financial Results

Snap Inc. reported third quarter 2026 financial results, achieving a return to profitability with net income of $56 million compared to a net loss in the prior year. Revenue grew 14% year-over-year to $1.72 billion, driven by progress in its advertising platform and AI investments.

Term
Q3 2026

“In Q3, we generated positive net income as revenue grew 14% year-over-year to $1.72 billion, reflecting the progress we are making to build a more profitable business. AI is becoming a significant advantage for our teams and advertising platform, and we continue to strengthen our business while investing in our long-term vision for augmented reality with the launch of SPECS.”

Evan Spiegel, co-founder and CEO
4:12 PM ET 8-K
Financial Results e.l.f. Beauty, Inc. ELF

e.l.f. Beauty Financial Results

e.l.f. Beauty reported second quarter fiscal 2027 net sales of $520.8 million, a 51% increase year-over-year driven by strength in retail and e-commerce channels. The company raised its full-year fiscal 2027 net sales growth guidance to a range of 22% to 24%.

Term
Q2 2027

“I am proud of the e.l.f. Beauty team for delivering our 31st consecutive quarter of net sales growth, with net sales up 51% driven by strength across our portfolio. With this momentum, we are raising our full-year net sales guidance to 22 to 24 percent.”

Tarang Amin, e.l.f. Beauty Chairman and CEO
4:12 PM ET 10-Q
Financial Results Unum Group UNM

Unum Group Q3 2026 Results: Net Loss of $420M

Unum Group reported total assets of $61.3 billion as of September 30, 2026, a decrease from $63.5 billion at year-end 2025. The company maintained a strong equity position of $10.8 billion despite a significant increase in treasury stock holdings, while premium income for the third quarter of 2026 reached $2.8 billion.

Key figure
Net loss $420M
4:12 PM ET 10-Q
Financial Results Omnicell, Inc. OMCL

Omnicell Q3 2026 Results: Net Income $11M, Up 102.2% YoY

Omnicell reported total revenues of $929.9 million for the nine months ended September 30, 2026, a significant increase from $870.9 million in the prior year period. Net income for the same period rose sharply to $46.7 million compared to $4.1 million in 2025, driven by improved gross margins and controlled operating expenses.

Key figure
Net income $11M · +102.2% YoY
4:12 PM ET 10-Q
Financial Results Design Therapeutics, Inc. DSGN

Design Therapeutics Q3 2026 Results: Net Loss of $20.3M, Loss Widens

Design Therapeutics reported a net loss of $20.3 million for the third quarter of 2026, driven by $22.2 million in operating expenses primarily for R&D. The company maintained a strong liquidity position with $208.6 million in cash and investments, which management expects will fund operations for at least 12 months.

Key figure
Net loss $20.3M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.